Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia

References

• Wilson PK, Szabados E, Mulligan SP, Christopherson RI. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines. Int J Biochem Cell Biol 1998;30:833–842.
   PubMed Web of Science ®Google Scholar
• Wilson PK, Mulligan SP, Christopherson RI. Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. Leuk Res 2004;28: 725–731.
   PubMed Web of Science ®Google Scholar
• Lindemalm S, Liliemark J, Juliusson G, et al. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 2004;210:171–177.
   PubMed Web of Science ®Google Scholar
• Goede V, Humphrey KF, Asikanius E, et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial. J Clin Oncol 2013;31(Suppl.): Abstract 7004.
   Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114:3382–3391.
   PubMed Web of Science ®Google Scholar
• Mulligan SP, Gill DS, Turner P, et al. A randomised dose de-escalation safety study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged 65 years – end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 study. Blood 2012; 120(Suppl. 1): Abstract 436.
   PubMed Web of Science ®Google Scholar
• Carney DA, Mulligan SP. Chronic lymphocytic leukaemia: current first-line therapy. Intern Med J 2009;39:44–48.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Factsheets: Leukemia. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/leuks.html
   Google Scholar
• Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- - D-erythro-pentofuranosyl)purines. J Med Chem 1972;15:735–739.
   PubMed Web of Science ®Google Scholar
• Carson DA, Piro LD, Wasson DB, et al. Activity of 2-chloro- 2’-deoxyadenosine in chronic lymphocytic leukemia, hairy cell leukemia, and autoimmune hemolytic anemia. Adv Exp Med Biol 1989;253A:427–431.
   PubMedGoogle Scholar
• Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2’-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993;11:679–689.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia. N Engl J Med 1994;330:1828–1829; author reply 1829–1830.
   PubMed Web of Science ®Google Scholar
• Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995;9:1130–1135.
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069–1073.
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993;328:812–813.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723–2729.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Urbanska-Rys H, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999;13:518–523.
   PubMed Web of Science ®Google Scholar
• Laurencet F, Ballabeni P, Rufener B, et al. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin’s lymphomas. Acta Haematol 2007;117:40–47.
   PubMed Web of Science ®Google Scholar
• Delannoy A. Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993;328:812; author reply 813.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Elmhorn-Rosenborg A, Liliemark L. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327:1056–1061.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160–2166.
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinka-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996;22: 509–514.
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinska-Morawiec M, Blonski JZ, et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur J Cancer 1997;33:2347–2351.
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinska-Morawiec M, Blonski JZ, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999;34:151–157.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001;15:1510–1516.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002;3:244–250.
   PubMedGoogle Scholar
• Robak T, Blonski JZ, Kasznicki M, et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit 2005;11: PI71–PI79.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006;108: 473–479.
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010;28:1863–1869.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma 2013 Nov 14. [Epub ahead of print]
   Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Juliusson G, Eksborg S, et al. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Cancer Chemother Pharmacol 1996;38:536–540.
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A, Group EQoL, Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38(Suppl. 4):S125–S133.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Derogar M., van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol 2012;51:10–16.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Obwandner T, et al. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 2007;25:1722–1731.
   PubMed Web of Science ®Google Scholar
• Else M, Cocks K, Crofts S, et al. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma 2012;53:1289–1298.
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, O’Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003;97:114–120.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Blood 2012;120(Suppl. 1): Abstract 435.
   Google Scholar